Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

April 8, 2025 Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. April 8, 2025 New Study Published in Clinical Cancer Research Validates ...

The aim was to compare serum TST recovery between LHRH agonists and LHRH antagonists. A total of 131 patients who underwent radiation therapy with ADT for prostate cancer were retrospectively analyzed ...

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors. The U.S. Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate ...

99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models – ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy ...

99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in ...

Share on Pinterest Skipping cancer screenings may contribute to a higher mortality rate from prostate cancer, new research suggests. jamesbenet/Getty Images Men who often miss their prostate ...